5 Key Values: Confidence in Your Ideal CRO Partner

CRO checklist
By The Editors at Uncommon Conversations,

  Did you know that, by next year, 72% of trials are projected to be outsourced to contract research organizations (CROs)? We add value throughout the process: protocol design, study planning, feasibility, insights into sites, investigators, patient populations, common challenges, etc. They turn to us to accelerate their timelines, reduce costs and de-risk the study. There is a lot on the line. In this blog post, Worldwide Clinical Trials previews its recently developed checklist which lists the 5 most important values you need from your ideal CRO partner.

Read More

Rare and Orphan Disease Research and What It Means for Oncology Drug Development

Scientist Looking At Orphan Disease Research
By Mireille Cantarini, BSc, MB ChB, MRCP, FFPM, Vice President, Therapeutic Area Operational Strategy Lead, Hematology and Oncology,

  Extensive research and drug development lies at the core of modern medicine. However, when it comes to an orphan indication or rare disease research and drug development, big pharmaceutical organizations are reluctant to invest because of perceived limited commercial viability. Our latest blog explores why it matters to invest in orphan disease research and development and what it means for clinical researchers in the oncology space.

Read More